# Tesamorelin: The Science-Backed Growth Hormone Peptide for Fat Loss and Longevity
Tesamorelin occupies a unique position in the peptide landscape: it's one of the only growth hormone-releasing hormone (GHRH) analogs with genuine FDA approval, a stack of randomized controlled trials, and real-world outcomes that practitioners consistently replicate. If you're serious about visceral fat reduction, metabolic optimization, or longevity protocols, tesamorelin deserves a close look.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), a 44-amino-acid peptide naturally produced in the hypothalamus. Where native GHRH degrades rapidly in circulation (half-life under 7 minutes), tesamorelin's modified structure extends its half-life and metabolic stability — allowing a once-daily injection to produce sustained pulsatile GH secretion throughout the day.
The FDA approved tesamorelin (brand name Egrifta) in 2010 for HIV-associated lipodystrophy — a condition marked by excess visceral adipose tissue (VAT) accumulation. That clinical origin is important: it means tesamorelin's visceral fat effects aren't theoretical. They're documented across multiple large, placebo-controlled human trials.
How Tesamorelin Works
Rather than directly administering synthetic growth hormone, tesamorelin works upstream — stimulating the pituitary gland to produce and release GH in physiologic pulses. This approach preserves the natural feedback loop between GH and insulin-like growth factor 1 (IGF-1), which is what makes tesamorelin meaningfully different from exogenous HGH.
The downstream effects of GH release relevant to body composition include:
- Lipolysis activation — GH binds to fat cell receptors, triggering breakdown of stored triglycerides, with visceral adipose tissue being particularly responsive
- IGF-1 elevation — Hepatic IGF-1 rises, promoting lean mass retention and cellular repair
- Improved insulin sensitivity — Fat reduction, particularly visceral fat, directly reduces insulin resistance
- Collagen synthesis support — GH stimulates connective tissue repair and skin integrity, contributing to the anti-aging interest in GHRH peptides
Tesamorelin does not suppress the HPG (hypothalamic-pituitary-gonadal) axis. It doesn't affect testosterone or estrogen production. For men and women using it as part of a broader optimization stack, this is a meaningful advantage over other peptides that carry endocrine suppression risk.
Clinical Evidence: What the Trials Show
The strongest tesamorelin data comes from the LIPO studies — large, randomized, double-blind, placebo-controlled trials enrolling HIV+ patients with documented visceral lipodystrophy. Key findings:
Visceral Fat Reduction
- 26-week trial: Tesamorelin 2mg/day reduced VAT by approximately 15% vs 5% in placebo (p<0.0001)
- 52-week extension: Patients who continued tesamorelin maintained VAT reduction; those who switched to placebo saw reversal within 26 weeks
- Average absolute reduction: 37 cm² of visceral adipose tissue at 26 weeks
IGF-1 and GH Outcomes
- IGF-1 increased by approximately 95–105 ng/mL from baseline, remaining within the normal physiologic range
- No cases of IGF-1 supraphysiologic elevation at standard dosing in trial populations
Lipid Panel Effects
- Triglyceride reductions seen in a subset of patients, particularly those with baseline hypertriglyceridemia
- No clinically significant change in LDL or HDL at standard doses
Lean Mass
- Modest but consistent increases in lean body mass (approximately 1–1.5 kg over 26 weeks) without caloric intervention
Outside the HIV population, investigator-initiated studies and registry data from longevity-focused clinics show similar visceral fat outcomes in metabolically healthy adults with abdominal adiposity — which has driven off-label use in the wellness and performance medicine space.
Tesamorelin vs. Other GHRH Peptides
The GHRH peptide space includes several options: CJC-1295, Sermorelin, and ipamorelin (a GHRP). Here's where tesamorelin fits:
| Peptide | Type | VAT Evidence | IGF-1 Elevation | FDA Status |
|---|---|---|---|---|
| Tesamorelin | GHRH analog | Strong RCT data | Moderate, physiologic | FDA-approved |
| CJC-1295 | GHRH analog | Limited human data | Moderate to high | Research only |
| Sermorelin | GHRH (1-29) | Mostly animal/case | Low to moderate | Compounded |
| Ipamorelin | GHRP | No VAT-specific data | Low | Research only |
Tesamorelin's advantage is evidence depth. No other GHRH analog has phase 3 randomized trial data specifically on visceral fat in humans.
Dosing Protocol
Standard clinical dosing used in trials and most optimization protocols:
- Dose: 1–2 mg subcutaneous injection once daily
- Timing: Before bed (aligns with natural GH pulse; fasting state maximizes pituitary response)
- Cycle length: Minimum 12 weeks to assess visceral fat response; many run 6-month cycles
- Reconstitution: Bacteriostatic water at standard peptide reconstitution ratios
Some practitioners use 1 mg/day for maintenance or as an entry dose, stepping up to 2 mg if response is insufficient after 8–10 weeks.
What to avoid:
- Injecting within 2–3 hours of a carbohydrate-heavy meal (insulin elevation blunts GH pulse)
- Combining with glucocorticoids (reduce GHRH response)
- Use in patients with active malignancy (GH axis stimulation is contraindicated)
Side Effects and Safety Profile
In clinical trials, tesamorelin was generally well tolerated. Reported adverse effects:
- Injection site reactions (most common): mild erythema, bruising (~20% of trial participants)
- Fluid retention / edema: seen in a subset, usually mild and transient
- Arthralgias / myalgias: joint or muscle aches reported in ~10% at 2mg dosing
- Carpal tunnel-like symptoms: rare at standard dosing; more common at higher doses or in predisposed individuals
- Glucose: mild IGF-1 increases can theoretically reduce insulin sensitivity; monitor HbA1c in metabolic syndrome patients
Tesamorelin does not cause the severe GH side effects associated with exogenous recombinant HGH (e.g., acromegaly-like changes, sustained supraphysiologic IGF-1). The pulsatile pituitary-driven release keeps IGF-1 within normal physiologic range.
